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Abstract
The execution of a multisite trial frequently includes image collection. The Clinical Trials Processor (CTP) makes
removal of protected health information highly reliable. It also provides reliable transfer of images to a central
review site. Trials using central review of imaging should consider using CTP for handling image data when a
multisite trial is being designed.
Translational Oncology (2014) 7, 36–39
Introduction
Imaging plays a critical role in performing clinical trials for most
cancers. In multisite trials, independent central review of the images
has been shown to produce more consistent results than local review
by the individual image acquisition sites themselves [1]. Although
central review typically increases the cost per subject of a multisite
trial, the improved results, coupled with the opportunity to archive
the images for analysis in other contexts, can reduce total study costs
and make it the preferred approach.
To preserve the integrity of the data, modern clinical imaging
trials and image archive projects in cancer research will typically
store, process, and transmit the image data in their original digital
form. Although handling data in this way can be very efficient,
special tools are required to ensure that the quality and reliability
of the data are preserved and the regulatory requirements of Health
Insurance Portability and Accountability Act (HIPAA) are met. In
this paper, we describe tools developed by the Radiological Society
of North America (RSNA; Oak Brook, IL) [the Image Sharing
Network (ISN) and Clinical Trials Processor (CTP)] to address
these challenges.
Clinical Trial Dataflow
The simplest dataflow topology for a multisite clinical imaging trial is
a single principal investigator site surrounded by a constellation of
image acquisition sites. The image acquisition sites are responsible
for recruiting patients who meet the criteria of the trial, performing
the examinations, and transmitting the data to the principal investi-
gator site. The principal investigator site is responsible for validating,
organizing, archiving, and analyzing the data and making the data
and the analytic results available to the sponsor of the trial. This basic
design has been described in [2].
Confidentiality and Deidentification
Almost all image acquisition sites use their standard clinical infor-
mation systems to register the patient and then order, schedule,
and perform the examinations. The data objects produced in this
process therefore contain real-world identifiers—identifiers that
connect the data objects to the human being who was the trial sub-
ject. Such identifiers are known in HIPAA parlance as protected
health information (PHI). Descriptions of HIPAA and PHI are
outside the scope of this paper. For more information on HIPAA
and PHI, we refer you to http://www.hhs.gov/ocr/privacy/hipaa/
understanding/summary/.
Because the HIPAA privacy regulations impose strict requirements
on anyone who possesses PHI, Institutional Review Board (IRB)
tightly restrict usage of PHI in clinical trials and rarely allow PHI
to be transmitted to other institutions, so PHI must normally be re-
placed with research identifiers. A full description of HIPAA require-
ments for deidentification can be found at http://www.hhs.gov/
ocr/privacy/hipaa/understanding/coveredentities/De-identification/
guidance.html. Thus, before transmission to the principal investigator
site, the data objects must be modified to remove unnecessary PHI
and to replace necessary PHI with pseudonyms that preserve the re-
lationships among the data objects while breaking the connection
between the data and the human being who was the trial subject.
This process is formally termed “deidentification” and is technically
“pseudonymization” because there is an identifier for each subject,
Address all correspondence to: Bradley J. Erickson, MD, PhD, Department of Radiology,
Mayo E2, 200 First St SW, Rochester, MN 55905. E-mail: bje@Mayo.edu
Received 10 December 2013; Revised 10 January 2014; Accepted 15 January 2014
Copyright © 2014 Neoplasia Press, Inc. All rights reserved 1944-7124/14/$25.00
DOI 10.1593/tlo.13799
www.transonc.com
Trans la t iona l Onco logy Volume 7 Number 1 February 2014 pp. 36–39 36
but in common parlance, it is known as “anonymization,” and systems
that implement this process are often called anonymizers.
Most medical images are encoded according to the Digital Imaging
andCommunications inMedicine (DICOM) standard (http://medical.
nema.org/standard.html). DICOM defines a dictionary of several thou-
sand elements, each of which is designed to contain a specific type of
information (e.g., patient name, patient ID, image pixels, and other data).
A typical image includes fewer than 100 such elements, but there is ef-
fectively no limit. Additionally, the standard provides a mechanism for
including nonstandard, so-called private elements, with contents that
are not constrained by the standard. PHI is intended to appear in many
standard elements, and of course, PHI can appear in any private element.
The HIPAA privacy regulations provide the following two methods
for deidentifying data objects: the Safe Harbor Method and the
Statistical Method. The Safe Harbor Method defines 18 categories
of PHI and requires that data in all those categories be removed or
replaced with pseudonyms (see Table 1). This approach requires
the removal of information (e.g., patient age or sex) that is often
necessary for the data to be useful in a trial. The Statistical Method
allows some PHI to be preserved if it can be demonstrated that it is
insufficient to identify the human being who was the trial subject.
The deidentification of a DICOM object is an arcane and techni-
cal task requiring an understanding of the DICOM standard and
sometimes even knowledge of the provenance of the data. Part 15
of the DICOM standard now defines a set of deidentification profiles
that specify procedures for deidentifying objects in various circum-
stances. The most stringent profile, the Basic Profile, generally removes
all PHI as required by the Safe Harbor Method, often more than is
appropriate for a specific trial. Other profiles preserve certain categories
of PHI. In many trials, one or more of these profiles are overlaid on the
Basic Profile to retain the necessary data while preserving the anonym-
ity of the trial subjects.
Clinical Trials Processor
The RSNA has developed a specialized tool, CTP, to support the
dataflow for clinical trials. CTP organizes related communication
and data processing functions into ordered sequences called pipelines.
Data objects are thought of as flowing down a pipeline, encountering
each pipeline stage in turn. CTP includes 35 standard pipeline stages
in four categories (import services, data processors, storage services,
and export services). Using CTP’s configuration editor, stages can
be arranged in pipelines and configured to implement the desired
dataflow for image acquisition sites and principal investigator sites.
CTP includes several stages to deidentify DICOM images:
 The DicomAnonymizer stage implements all the deidentification
profiles defined in the DICOM standard (ftp://medical.nema.
org/medical/dicom/final/sup55_ft.pdf). This stage is highly con-
figurable, allowing a clinical trial administrator to adapt it as
required by a specific trial.
 The DicomPixelAnonymizer stage blanks regions of images
containing PHI burned into the pixels. This stage uses nonpixel
information in the data object to identify the manufacturer and
model of the image device and blanks the regions defined in a
dictionary for that model.
 The DicomMammoPixelAnonymizer stage blanks PHI burned
into mammography images by examining the pixels directly.
CTP has been employed in numerous multisite trials and other
imaging-related research. One of the largest is the National Cancer
Institute’s Cancer Image Archive [3].
Audit Requirements
The Food and Drug Administration (FDA) imposes regulations on
medical software and data management. Title 21 of the Code of
Federal Regulations, Part 11 (21CFR11), applies to records in elec-
tronic form. In 21CFR11-compliant clinical trials, it is necessary to
log changes made to data objects, such as the changes made by an
anonymizer [4]. CTP provides an audit logging mechanism that is
used by several of its pipeline stages to meet that requirement.
Data Transmission
The transmission of data from image acquisition sites to the principal
investigator site is typically accomplished through the Internet, though
compact disks were commonly used in the past. Although data are
normally deidentified before transmission, most trials nevertheless use
encrypted communication and site authentication to minimize the
possibility of intercept. The CTP import service and export service pipe-
line stages support both encrypted and unencrypted communications.
In the modern Information Technology (IT) environment, it is
critical that hospital systems be protected from outside attack. This
typically requires blocking any unsolicited data being transferred into
a hospital computer. In a clinical trial, the receipt of image data at the
central site is usually an asynchronous and unsolicited event, and
such a restriction would make that impossible. To address this chal-
lenge, many central sites place a receiver outside the hospital’s restric-
tive firewall and poll the receiver from the internal network. This,
however, requires specialized IT support that is sometimes unavail-
able from heavily taxed IT departments. Another solution is to use
an Internet-based intermediary. An example of such an intermediary
is a cloud storage mechanism like Google Drive (Google; Mountain
View, CA) or Dropbox (Dropbox, Inc, San Francisco, CA).
The ISN
Although all these transmission alternatives are currently in use in trials
employing CTP, the RSNA has developed a more sophisticated
Table 1. HIPAA PHI Identifiers.
1. Name and last name
2. All geographical subdivisions smaller than a state, except for the initial three digits of the ZIP
code if more than 20,000 people population
3. All dates (excluding year) for individuals younger than 90 years. All dates associated with an
individual (birth date, admission date, discharge date, and death date).
4. Telephone numbers
5. Fax numbers
6. Email address
7. Social Security number
8. Medical record number
9. Health plan ID number
10. Patient account number
11. Certificate/license plate number
12. Vehicle identifier and serial number
13. Device identifier and serial number
14. Web universal resource locators
15. Internet protocol address
16. Biometric identifiers (fingerprints and voiceprints)
17. Patient photographic images
18. Any other identifying code
HIPAA §164.514(b) specifies 18 categories of data that are considered as potentially identifying
(taken from http://www.gpo.gov/fdsys/pkg/CFR-2011-title45-vol1/pdf/CFR-2011-title45-vol1-
sec164-514.pdf, page 885).
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approach on the basis of the Cross-Enterprise Document Sharing
(XDS) transfer protocol defined by the Integrating the Healthcare
Enterprise (Oak Brook, IL; see http://IHE.net) initiative. This ap-
proach uses a separate server and special-purpose CTP stages, all
developed by the RSNA’s ISN project. An Internet-based commercial
XDS Repository (the clearinghouse) serves as an intermediary to receive
submissions from image acquisition sites and supplies them to principal
investigator sites when polled. This is effectively like the model de-
scribed above where images are collected by a server outside the firewall,
but rather than being required for each hospital, it is a central resource
supported by the ISN project.
The ISN system uses CTP to provide the anonymization and site-
based image transfer capabilities but uses XDS and the clearinghouse
to transmit images between sites. As such, the functionality will be
similar to that of CTP but eliminates the need for a central site to
have a CTP receiver that is visible outside its firewall. From that per-
spective, any site that has ISN implemented will likely find it pref-
erable to use the ISN for research purposes because it eliminates to
purchase and maintain that extra server.
Central Site Management
When the images have been transmitted to the central site, the cen-
tral site typically validates the data to ensure that the imaging pro-
tocol was followed and that artifacts (e.g., motion) do not render the
images unusable.
Adherence to the imaging protocol can largely be checked pro-
grammatically by comparing values in the DICOM metadata with
values required by the protocol. The specific Quality Assurance steps
used will vary with each clinical trial. Many will have specified
specific acquisition parameters [e.g., slice thickness for computed
tomography (CT) and magnetic resonance (MR); peak kilovolts
(Kvp) and milliamperes (mA) for CT; and TR, TE, and slice orien-
tation for magnetic resonance imaging (MRI)], and these can be
programmatically or manually checked on receipt of a study. CTP
provides several pipeline stages that can be used to accomplish these
checks. Checking for motion artifacts programmatically is more
challenging, but it has been reported to be useful [5].
Once these quality assurance (QA) checks are completed, the mea-
surement and analysis phase can be started. The exact measurements
vary with each protocol; many cancer studies will simply want Response
Evaluation Criteria in Solid Tumors (RECIST) measurements made,
but there is increasing interest in measuring tumor volumes. The FDA
requires that a record be maintained of the receipt of, and all changes
made to, data that is part of a submission for a drug or device approval.
In the context of the processing of image data for clinical trials, this audit
trail must document the versions of the software used, including any
scripts that control the anonymization that was performed. In the extreme
case, the audit trail must include every individual change made in each
image. Such audit trails can be created automatically by many electronic
tools, including CTP. If the analysis involves more than a few steps,
workflow technologies can execute automated steps or provide task lists
for human operators. Such a system could also help to guide the user
on the correct next steps as well as automatically document the data
measurements and manipulations [6].
Using the CTP
The CTP tool is extremely flexible, but with that flexibility comes
complexity. Here, we present a common use case of a multisite
Figure 1. Configuration screen for a typical CTP installation for
a submitting site. From this screen, one can view and edit the
various components of CTP, including the pipeline(s) being used,
and the components within a pipeline.
Figure 2. Example of a lookup table file used by CTP for mapping
from the local medical record number to the subject ID. In this
example, there is a SiteID component as well as a local subject
component, but that is not required.
Figure 3. Portion of the PixelAnonymizer configuration file for CTP.
This section applies to images from a General Electric Advantage
Windows © workstation and specific types of images that it can
produce. In this case, it looks at tags in the DICOM header to char-
acterize the type of image and then specifies the rectangle on the
image that contains PHI.
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clinical trial and specifically how to use CTP to enable that clinical
trial. The basic assumptions of this use case are that there are N sites
participating (“submitter”), each with its own set of research subjects
who will be getting one or more imaging examinations that will be
transmitted to a central analysis site. We also assume that there is
exactly one central analysis site. We assume that each submitter will
keep the PHI of their patients at their site and that they have a re-
search ID that will be used to identify each subject to the analysis
site. That research ID should be encoded into the image file to max-
imize the integrity of the process.
When CTP-installer.jar is downloaded (from http://mirc.rsna.org/
query) and executed, it will recognize if it has not been installed
before into the selected location. In that case, it will display the “help
page” for CTP, which asks the user to select a pipeline. Figure 1 shows
the configuration screen for CTP. For a multisite trial where data are
sent to another site, the user would select “Image Acquisition Site” (a
central site would select “Principal Investigator Site”). Within this pipe-
line, the user may configure the anonymization options to use, as well
as information about how it will receive information from the Picture
Archive and Communications System (PACS; DicomImportService).
In most cases, the individual sites will have a mapping from their
local identifier to the research identifier. The “lookupTable” field in
the DicomAnonymizer option of CTP points to the file where that
lookup table exists. When a file is transferred to CTP, CTP will look
up the medical record number in that file and replace it with the
research identifier. It will then also remove other PHI elements
according to the instructions specified in the “script” that is a file
pointed to by the “scripts” field in the pipeline. An example of such
a file is shown in Figure 2 (to comply with HIPAA, there are no real
Medical Record Numbers but text that indicates these).
Removing information from the DICOM tags is fairly straight-
forward, but CTP cannot only remove information, but can also
insert calculated values. For instance, a study could add a private but
known offset to the date of birth so that only members of the study
with that private information would know the correct date of birth.
This allows preservation of information without disclosing PHI.
CTP also enables removal of information from portions of an
image, depending on the vendor and model of device. The database
of devices/models and where they typically “burn in” PHI is supplied
with CTP and can easily be included as part of the pipeline. And
example of this is shown in Figure 3. In the past, such “burned
in” information was common for all images. Now, it is occasionally
seen with fluoroscopy and ultrasound images and increasingly with
postprocessed images like three-dimensional (3D) renderings.
Other Options for Clinical Trials That Use Images
There are no other free and open-source tools built specifically for
multisite trials with anonymization and image transfer. The American
College of Radiology (Reston, VA) has developed a robust tool for
image transfer called TRIAD, but that is proprietary. There are several
open-source tools, as well as free and commercial tools for anonymiz-
ing studies. Most of these do a very good job of handling the standard
DICOM tags. Few have a robust mechanism for removing all private
tags, except those known to be safe. This is critical because many re-
search studies wish to use cutting-edge imaging methods where
DICOM standards for storing the scanning parameters may not be de-
fined. Until they are defined, vendors typically store the information
in private tags that become known fairly quickly. It is critical that ano-
nymization softwares have a database of “known safe tags” to preserve
this information but remove the rest. CTP is implementing this,
and it should be available by the time this article is published. Sev-
eral free and open-source image-viewing softwares can anonymize
images, including ImageJ, ClearCanvas (Toronto, CA), and OsiriX
(Geneva, Switzerland). Another option focusing on just anonymiza-
tion is shown in http://www.dclunie.com/pixelmed/software/webstart/
DicomCleanerUsage.html.
In some cases, PHI may also be “burned into” the pixels of the
image, and proper anonymization also requires removal of this. It
is possible to use image editing software to “black out” these pixels,
but CTP is the only software we are aware of that has a database of
where PHI is placed in images, based on the vendor and model of
the imaging device.
Conclusion
Images are important for the conduct of many clinical trials. They are
often used for documenting the response of a tumor to therapy or for
decision making in a clinical trial—to determine whether a subject is
eligible or to determine whether a condition that requires a change in
therapy has been reached. Implementing an efficient dataflow in a
multisite clinical trial while meeting privacy regulations requires spe-
cial tools. Here, we have described open-source software that helps
researchers to implement such a system.
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